Ask a question about this product
Neulasta Biosimilars – Target Pipeline List 11/2018
Target: Granulocyte Colony Stimulating Factor (G-CSF) Receptor
This report provides a comprehensive overview of long-acting G-CSF receptor agonists as biosimilars of Neulasta (pegfilgrastim) from Amgen in regulated and in less regulated markets as well as of novel, potentially biosuperior, long-acting G-CSF receptor agonists for treatment of chemotherapy-induced neutropenia.
The world market of G-CSF products in the year 2017 was worth over US$ 5.5 bln, mostly due by global Neulasta sales of US$ 5.93 bln achieved by Amgen and Kyowa Hakko Kirin Pharma. Patent expiration of Neulasta has commenced in the European Union and numerous developers are ready to enter the attractive Neulasta market. The first Neulasta biosimilar products have been approved in Europe, the USA and in Canada. Neulasta biosimilars are already available on less regulated markets.
La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables. The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.
The Target Pipeline List in the Word table contains information about:
File: ID no. in proprietary database
Drug name: trade name, INN, drug code(s), trivial name
Target/MoA: mechanism of action
Class of compound: description of type of molecule, formulation, way and mode of administration, application device
Company: originator of molecule and licensee(s) with territories
Category: treatment modalities, i.e. antibody, protein, peptide, RNA, DNA, cells, vaccine, small molecule
Indication: medical indication evaluated in preclinical or clinical study, combination regimens
R&D Phase: from research to market with reference to indication/study
Message: last verified information about project with source and date of information and hyperlink leading to source of information
Information about R&D projects is identified and retrieved from company publications including, but not limited to, press releases, presentations, website disclosures, SEC publications, regulatory documents, scientific abstracts and full papers, patent applications. Furthermore, public and proprietary databases are used including national and regional clinical trial databases, PubMed.